CD44 and breast carcinoma: Since this study revealed that, notably, three out of four TNBC and other breast cancer cell lines show a good response to FEN1-IN-4 monotherapy and combination therapy with IR, FEN1-IN-4 may expand the therapeutic spectrum as a potential target therapy.